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Aim: Male breast cancer (MBC) is a rare disease and recommendations for its clinical management are
often extrapolated from those for female breast cancer, even if breast cancer (BC) has different charac-
teristics in the two sexes. The purpose of this study was to assess the influence of several individual
characteristics including clinico-pathological, lifestyle and genetic factors on overall survival (OS) of a
relatively large and well characterized population-based series of 166MBCs enrolled in Tuscany.
Methods: We genotyped MBC cases at BRCA1/2 genes and at 9 candidate BC susceptibility SNPs. Kaplan-
Meier method and multivariate Cox regression, adjusted for several individual characteristics were used.
To reduce a possible selection bias related to the interval between diagnosis and enrolment of MBC cases
into the study, we used the date of blood donation as the date of the start of observation for survival
analysis.
Results: Only smoking habits had a significant effect on OS at 10 years (for current smokers, HR: 3.34;
95% CI 1.45e7.68; p¼ 0.004), while lymph node status fell short of reaching statistical significance (for
pN positive, HR: 2.07; 95% CI 0.93e4.55; p¼ 0.07). In the same multivariate analysis we found a
significantly higher OS in cases with FGFR2 rs2981582 variant in the dominant transmission model (HR:
0.29; 95% CI: 0.13e0.62; p¼ 0.028). A sensitivity analysis with left truncation showed similar results.
Conclusions: Our results may contribute to shed light on factors influencing MBC survival suggesting an
important role for cigarette smoking and FGFR2 rs2981582 variant, and provide clues for better patient
management.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
Male breast cancer (MBC) is a rare disease accounting for <1% of
all cancers in men [1]. Some studies suggest a worse outcome forst cancer; FBC, Female breast
S, Genome-wide association
, Kaplan-Meier method; HR,
putation; MICE, Multivariate
rowth factor receptor 2; PAH,
d break repair.
Lifestyle Epidemiology Unit,
l Network (ISPRO), Via delleMBC patients compared with female breast cancer (FBC) cases,
largely due to delay in diagnosis and associated comorbidities for
the advanced age of the patients [2]. Furthermore, depending on
the paucity of data, recommendations for MBC are often extrapo-
lated from those for FBC. Nevertheless, even if MBC and FBC share
similarities in terms of genetic, environmental and lifestyle risk
factors, BC is biologically different in the two genders [3,4]. Thus,
there is the need to better understand this disease identifying
male-specific factors influencing survival and providing the basis
for a better patient management.
Most of the retrospective studies evaluating “traditional”
clinico-pathological prognostic factors of MBCs show conflicting
results [5-7]. Individual characteristics such as age and marital
status have been detected as independent prognostic factors for
MBC survival in some studies [8, 9]. Among lifestyle factors, the
I. Zanna et al. / The Breast 40 (2018) 85e9186impact of tobacco smoking has not yet been fully elucidated. A
recent study carried out on 1,573 MBC cases provided the first ev-
idence that smokers at the time of diagnosis have a worse survival
than never smokers, with a significant linear dose-response of
smoking intensity [10]. In the effort to identify predictors of MBC
survival, host genetic characteristics cannot be ignored. Results on
prognostic significance of BRCA mutations are not consistent [11-
13] and in FBC, the relationship between susceptibility SNPs,
identified in genome-wide association studies, and prognosis is not
yet been established with some exceptions [14, 15].
To our best knowledge, no study on the association among SNPs
and survival in MBC series has been performed. In a previous study,
we tested nine susceptibility variants identifying common variants
at ESR1 and TOX3 loci playing a role in MBC susceptibility [4]. Thus,
we hypothesized that these SNPs might also be associated with
MBC prognosis. The aim of this study was therefore to assess
whether different individual characteristics, including selected
genetic and lifestyle factors, affect survival in a well-characterized
population-based series of 166 MBC cases, enrolled in Tuscany
(Central Italy).
2. Material and methods
2.1. MBC patients recruitment
In the present study, we expanded the original population-
based series of 108 MBC cases previously described [16] enrolling
58 additional MBC cases, diagnosed in the period 1980e2015, for a
total of 166MBCs residing in Tuscany.
The recruitment of the newcaseswas carried out according to the
same protocol used for the previous MBC series. Overall, after
exclusionof deceased andmigratedpatients, 63 additional unrelated
MBCwere traced and invited to participate into the study. Five cases
refused to participate, mostly because of advanced age or severe
illness, thus confirming our previous high response rate (92.1%).
For each study participant we obtained: 1) a signed informed
consent form; 2) detailed information on his personal and familial
history of cancer at any sites validated by the local Cancer and
Mortality Registries; 3) information on lifestyle habits, collected by
standardized EPIC questionnaires [17]; 4) a detailed occupational
history up to the date of MBC diagnosis; 5) a peripheral blood
sample.
Clinico-pathological data were collected through several ap-
proaches, including retrieval of medical records and pathological
reports. Some individual data were not available for all cases.
Procedures to maintain confidentiality for all information
collected were developed and strictly applied. The study was
approved by the Florence Ethical Committee (prot. 0001192/2006).
2.2. DNA extraction, mutation analysis and genotyping
For each study participant DNA was extracted from peripheral
blood lymphocytes using QIAamp DNA Blood mini kit (Qiagen,
Venlo, The Netherlands), following manufacturer instructions. DNA
samples were quantified using NanoDrop 1000 (Thermo Fisher
Scientific, Waltham, Massachusetts, USA).
The entire BRCA1 and BRCA2 coding sequences were analyzed
by combining single strand conformational polymorphism (SSCP),
protein truncation test (PTT), and Sanger sequencing as previously
described [4]. All cases negative for BRCA1/2 mutations were
recently retested using Next Generation Sequencing [18]. All
BRCA1/2 variants classified as pathogenic mutations were
confirmed by Sanger sequencing. MBC cases were also genotyped
by allelic discrimination real-time PCR with TaqMan probes at nine
selected susceptibility SNPs as previously described [4].2.3. Statistical analysis
Study variables included interval between diagnosis and blood
donation, breast and/or ovarian cancer family history (FH), personal
history of other cancers, marital status, smoking habits, tumour
characteristics, BRCA mutational status and genotype of nine
selected susceptibility SNPs.
Descriptive statistics to evaluate patients’ characteristics were
used. One of the problems in MBC studies is represented by the
rarity of the disease. In order to increase the number of cases for
meaningful statistical analyses, it has been necessary to enrol pa-
tients diagnosed over a long period of time and in a larger
geographical area. To reduce a possible selection bias related to the
interval between diagnosis and enrolment of MBC cases into the
study, we used the date of blood donation as the date of the start of
observation for survival analysis. Survival time was calculated from
this date to the date of death from any cause (overall survival, OS) or
the last follow-up (May 2016) for alive patients. All current analyses
are focused on 10-year survival: all subjects alive at 10 years were
censored as those with a shorter follow-up (67 patients at the last
date). For each variable, OS was estimated using the Kaplan-Meier
method (K-M), and differences between groups of patients were
assessed by the log-rank test. Univariate Cox regression was also
used.
Furthermore, multivariate regression analysis was carried out to
assess the effect of each SNP according to either recessive or
dominant transmission model taking into account other individual
characteristics. In the dominant transmission model, both the
heterozygous variant and the rare homozygous variant were
combined in a dummy variable. In the recessive transmission
model, the rare homozygous genotype variant was defined in a
dummy variable. Multivariate Cox regression models including one
SNP at a time (in the recessive or dominant transmission model)
and selected individual characteristics were fitted with age as the
primary time variable.
We also performed a sensitivity analysis with survival time
beginning at the time of the diagnosis, adjusting for left truncation
(delayed entry of enrolledMBC cases) [19]. In our series, we defined
the left truncation time as the time from diagnosis to enrolment.
Since our dataset contained missing values for a few variables,
multiple imputation [20,21] was used to analyze the whole dataset.
As recommended by Rezvan et al. [22], we produced 100 imputed
datasets. P-values were adjusted using the Benjamini-Hochberg
procedure for multiple testing [23]. All calculations were made in
R 3.3.3 for Windows [24].
3. Results
3.1. Clinico-pathological and genetic characteristics
A total of 166 men with BC diagnosed between 1980 and 2015
were included in our study. Mean age at diagnosis was 64.3 years
(SD: 11.5; range 24e91 years). We enrolled the cases after a mean
interval diagnosis-blood donation of 4.7 years (SD: 4.4; median
3.6), thus the mean age at blood donation was 69 years (SD: 11.2).
Themain characteristics of MBC cases are shown in Table 1. Notably,
five patients (3.0%) had been diagnosed with bilateral BC. All MBC
cases were genotyped at BRCA genes and at nine susceptibility SNPs
(Table 2).
4. Survival analysis
4.1. Kaplan-Meier survival analysis and univariate Cox regression
In the follow-up, we identified 23 deaths at 5 years, and 51 at 10
Table 1
Distribution of patients and KaplaneMeier survival estimates according to selected individual characteristics (166 MBC patients, Tuscany, Italy).
N at start 5 yearsa 10 yearsa pevalue*
(%) Deaths At risk %OS Deaths At risk %OS
Interval diagnosiseblood donation
< median (3.6 years) 83 (50.0) 11 61 85.2 21 24 67.5
 median 83 (50.0) 12 51 83.0 30 26 50.1 0.100
BC/OC family history
Negative 88 (53.0) 11 66 86.0 32 29 54.5
Positive 78 (47.0) 12 46 81.7 19 21 64.8 0.566
Personal history of other cancers
Negative 138 (83.1) 18 96 85.2 40 43 61.1
Positive 28 (16.9) 5 17 77.5 11 7 42.6 0.132
Marital status
Single, widowed, separated or divorced 130 (7.8) 2 11 83.3 4 6 64.8
Married 153 (92.2) 21 102 84.2 47 44 57.5 0.640
Smoker
Never/Former 133 (80.1) 17 90 85.1 37 40 61.6
Current 33 (19.9) 6 23 79.7 14 10 47.6 0.274
Tumour behaviour **
In situ 17 (10.5) 0 14 100.0 1 6 88.9
Invasive 145 (89.5) 23 95 81.7 49 42 54.7 0.037
UICC Stage **
IeII 121 (85.8) 15 86 85.9 35 37 61.5
IIIeIV 20 (14.2) 4 13 77.3 8 7 48.2 0.435
Histological type **
Other 16 (10.0) 1 13 92.9 2 7 84.4
Ductal 144 (90.0) 21 95 83.0 46 42 56.1 0.094
Tumour grading **
I e II 100 (71.4) 10 72 88.7 29 33 60.2
III 40 (28.6) 8 27 77.2 14 11 54.0 0.374
pN **
Negative 78 (62.9) 10 52 84.8 15 28 73.6
Positive 46 (37.1) 9 29 78.0 20 8 41.9 0.006
ER**
Negative 140 (9.6) 4 12 73.3 8 8 46.7
Positive 132 (90.4) 13 90 88.1 32 39 64.0 0.039
PR**
Negative 23 (15.9) 1 20 95.5 8 10 56.3
Positive 122 (84.1) 16 82 84.6 32 37 64.0 0.864
HER2**
Negative 103 (81.7) 11 76 87.9 30 37 61.5
Positive 23 (18.3) 4 16 80.1 7 9 63.1 0.831
Biological type **
Luminal A 93 (70.4) 10 66 87.4 25 31 62.4
Luminal B 20 (22.0) 3 14 82.2 5 8 68.3 0.830
HER2 30 (2.3) 1 3 66.7 2 2 33.3 0.143
TN 70 (5.3) 0 1 66.7 2 5 66.7 0.780
All patients 166 23 112 84.0 51 49 58.2
*pevalue from the logerank test assessed at 10 years after enrolment.
**some data are missing.
a after enrolment into the cohort (date of blood donation).
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analysis according to selected characteristics: the 5-year OS was
84%, while 10-year OS was 58.2%. Survival curves with significant
log-rank tests are shown in Figure 1. Results from univariate Cox
regression models for ER and BRCA2 mutation status were consis-
tent with K-M survival analysis (p¼ 0.019 and p¼ 0.050, respec-
tively). The risk of death related to pN status resulted of borderline
statistical significance (p¼ 0.073). Among lifestyle factors, current
smokers showed a significant increased risk of death (p¼ 0.007)
(data not shown).
4.2. Multivariate Cox regression
In multivariate analyses we fitted several regression models,
each one including one SNP at a time (in the recessive or dominant
transmission model) adjusted for selected individual characteris-
tics and with age as the primary time variable. Only the regression
including fibroblast growth factor receptor 2 (FGFR2) rs2981582
variant in the dominant transmission model showed a significantdecreased risk of death at 10 years after enrolment (HR: 0.29; 95%
CI: 0.13e0.62; p¼ 0.028) (Table 3).
Among lifestyle factors, only smoking habits had a significant
effect on OS, with current smokers showing an increased risk of
death (HR: 3.34; 95% CI 1.45e7.68; p¼ 0.004). Difference in OS due
to lymph node status resulted only of borderline statistical signif-
icance (HR: 2.07; 95% CI 0.93e4.55; p¼ 0.071).
The sensitivity analysis with left truncation showed similar re-
sults. We found at 10 years after diagnosis a significantly increased
risk of death for current smokers (HR: 3.82; 95% CI 1.09e13.41;
p¼ 0.037) and a significantly decreased risk of death for FGFR2
rs2981582 variant in the dominant transmission model (HR: 0.32;
95% CI: 0.12e0.87; p¼ 0.026). After multiple comparison adjust-
ment the latter effect of FGFR2 rs2981582 variant did not reach the
level of statistical significance (data not shown).
5. Discussion
In this population-based series of 166 MBC enrolled in Tuscany
Table 2
Distribution of genotype frequencies and KaplaneMeier survival analysis according to BRCA mutational status and selected susceptibility SNPs (166 MBC patients, Tuscany,
Italy).
N at start 5-yearsa 10 yearsa pevalue*
(%) Deaths At risk %OS Deaths At risk %OS
BRCA status
Wild type 144 (86.8) 19 99 84.8 43 45 60.0
BRCA1 mutated 40 (2.4) 0 4 100.0 0 3 100.0 0.212
BRCA2 mutated 18 (10.8) 4 10 72.4 8 3 29.0 0.036
CASP8 rs1045485
GG 118 (71.1) 19 80 81.8 38 38 58.3
GC 44 (26.5) 3 30 91.6 12 12 56.8 0.746
CC 40 (2.4) 1 3 66.7 1 1 66.7 0.962
19p13 rs2363956
GG 42 (25.3) 8 26 78.3 15 9 51.6
GT 83 (50.0) 12 55 83.5 26 31 59.0 0.875
TT 41 (24.7) 3 31 91.4 10 12 62.9 0.365
2q35 rs13387042
GG 37 (22.3) 5 26 84.7 8 13 73.0
GA 79 (47.6) 8 56 88.2 23 25 59.6 0.480
AA 50 (30.1) 10 31 77.1 20 13 46.0 0.073
5p12 rs10941679
AA 93 (56.0) 14 64 83.2 30 28 57.0
AG 62 (37.4) 7 43 86.2 19 20 57.2 0.815
GG 110 (6.6) 2 7 76.2 2 4 76.2 0.594
ESR1 rs2046210
CC 51 (30.7) 5 37 88.4 16 15 55.1
CT 82 (49.4) 11 53 84.3 24 25 58.9 0.836
TT 33 (19.9) 7 23 77.3 11 11 62.1 0.768
FGFR2 rs2981582
GG 38 (22.9) 9 22 73.3 14 7 44.1
GA 82 (49.4) 11 52 83.8 26 24 55.9 0.668
AA 46 (27.7) 3 38 92.8 11 20 70.5 0.076
LSP1 rs3817198
TT 74 (44.6) 9 53 86.3 22 24 61.5
TC 70 (42.2) 11 43 81.4 22 19 54.0 0.466
CC 22 (13.2) 3 16 85.0 7 9 60.0 0.861
MAP3K1 rs889312
AA 77 (46.4) 9 54 86.6 25 23 54.9
AC 73 (44.0) 12 49 81.6 23 23 59.1 0.824
CC 160 (9.6) 2 10 81.8 3 6 72.7 0.499
TOX3 rs3803662
CC 55 (33.1) 8 35 83.2 15 17 63.2
CT 82 (49.4) 11 56 84.4 26 25 57.1 0.743
TT 29 (17.5) 4 21 84.9 10 10 53.6 0.911
All patients 166 23 112 84.0 51 49 58.2
*pevalue from the logerank test assessed at 10 years after enrolment.
a after enrolment into the cohort (date of blood donation).
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rs2981582 in the FGFR2 gene significantly affect OS.
Due to low incidence and limited research, little is known about
the factors affecting MBC survival, and to our best knowledge this is
the first population-based study addressing the subject.
Taking into account “traditional” clinico-pathological variables,
our multivariate survival analysis suggests, in line with other
studies [25], the importance of lymph node involvement in MBC
prognosis although it doesn’t reach statistical significance.
With regard to epidemiological variables, we found a worse
prognosis in current smokers compared to never/former smokers.
The relationship between smoking habits and survival in BC has
been extensively studied in females, mainly in Western countries,
with conflicting results. Some studies showed that current and
former smokers were at higher risk of all-cause death after BC
diagnosis, whereas others failed to report this association [26,27].
Moreover, it has been shown that smokers tend to have more co-
morbidities and more advanced disease than non-smokers, even
after adjustment for clinical characteristics [28]. The results of the
only study performed recently on 1,573 MBC cases showed a sig-
nificant inverse association of survival with smoking intensity, also
reported in FBC, and suggested that smoking might have moreinfluence on MBC than on FBC survival and that the effect of
smoking on survival could be affected by race, pointing to different
genetic and molecular pathways [10].
Notably, evidence provided by several studies indicates a rela-
tionship between occupational and environmental exposures and
MBC risk. Interestingly, in a previous study, we reported a modi-
fying effect on MBC risk due to occupational exposure to polycyclic
aromatic hydrocarbons (PAH), in subjects carrying BRCA2 germ-
line mutations [29].
Here, our results confirm that cigarette smoke, a mixture of
chemical compounds including PAH and other carcinogenic sub-
stances, might affect survival in MBC. This effect could be explained
by the genetic context of MBC, partly consisting of defective high-
and low-penetrance predisposition genes involved in DNA damage
response. In addition, the relationship between smoking and MBC
survival might be due to the negative effect of long-term smoking
on the immune system and to the estrogenic effect of some com-
pounds present in tobacco smoke that could be more relevant in
men, without reproductive and hormonal factors, than in women,
in whom anti-estrogenic effect of smoking has long been known
[30,31].
Some studies aimed to identify genetic markers associated with
Figure 1. Kaplan-Meier survival curves with significant logerank test for selected
variables in a series of 166 MBC patients enrolled in Tuscany (Italy).
Table 3
Estimates of the risk of death at 10 years based on a multivariate Cox proportional
regression including all the listed variables and the FGFR2 rs2981582 variant in the
dominant transmission model (166 MBC patients, Tuscany, Italy). Multiple impu-
tation via chained equations (100 imputed datasets) was used.
HRa 95% CI pevalue
Interval diagnosiseblooda donation
< median (3.6 years) 1.00
 median 1.46 0.73e2.91 0.280
Smoker
Never/Former 1.00
Current 3.34 1.45e7.68 0.004
Tumour behaviour
In situ 1.00
Invasive 2.77 0.35e21.59 0.331
Histological type
Other 1.00
Ductal 2.00 0.43e9.20 0.375
Tumour grading
I e II 1.00
III 0.79 0.35e1.78 0.572
pN
Negative 1.00
Positive 2.07 0.93e4.55 0.071
ER
Negative 1.00
Positive 0.45 0.17e1.18 0.106
PR
Negative 1.00
Positive 1.24 0.48e3.20 0.658
HER2
Negative 1.00
Positive 1.44 0.53e3.92 0.478
BRCA status
Wild type 1.00
BRCA1 mutation <0.01 e 0.997
BRCA2 mutation 1.73 0.66e4.53 0.264
FGFR2 rs2981582 (dominant model)
Wild type 1.00
Heterozygous/homozygous variant 0.29 0.13e0.62 0.028*
*pevalue adjusted using the BenjaminieHochberg procedure for multiple
comparison.
a assessed at 10 years after enrolment into the cohort (date of blood donation).
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study on the association among SNPs and survival inMBC series has
been performed.
In the frame of a large Italian multicenter study, we showed that
common lowpenetrance BC susceptibility allelesmodulateMBC risk
[4, 36]. Thus, in addition to epidemiological variables, we explored
the possible role of such variants in MBC prognosis. In this study, a
higher rate of survival was observed in patients carrying the variant
allele of rs2981582 in FGFR2 gene. The protein encoded by this gene
is a member of the fibroblast growth factor receptor family and is a
receptor tyrosine kinase involved in cell proliferation, differentia-
tion, migration, apoptosis and double strand break repair (DSBR)
[37,38]. FGFR2 was one of the first genes identified to be associated
with the susceptibility to BC inGWAS. Interestingly, in intron 2 of the
gene, up to eight variants have been identified, including rs2981582,
that are located in a linkage disequilibriumblock and aremore likely
to predispose patients to ER þ low grade BC [37, 39].
In the clinical field, high expression levels of cytoplasmic and
nuclear FGFR2 were associated with lower OS, but in patients who
received chemotherapy, high expression of FGFR2 was associated
with better prognosis [37, 40]. Probably, high expression of FGFR2
reduces DSBR activity, which may increase sensitivity to chemo-
therapeutic agents causing DSB formation such as doxorubicin and
etoposide [38].
To our best knowledge, the role of FGFR2 variants in MBC
prognosis have not been investigated so far. In a study performed
on FBC Tunisian cases, a higher OS rate was observed in patients
carrying the FGFR2 rs1219648 variant allele, reported to be in high
linkage disequilibrium (r2¼1) with FGFR2 rs2981582 in HapMap
database [41].
It is interesting to note that, in male patients with primary
prostate cancer, both previously cited FGFR2 SNPs were associated
with more favourable OS [42]. These results are consistent with our
findings and support the hypothesis that rs2981582 SNPmight play
a role in MBC survival.
The mechanism underlying the effect of rs2981582 SNP is still
unknown. The FGFR2 rs2981582 variant not only affects FGFR2
mRNA level by altering the binding of transcription regulators, but
is also involved in the increase of FGFR2 signalling activity [43] that
could affect downstream FGFR2 targets creating conditions for a
better survival.
In our study, no role for BRCA mutations emerged in multivar-
iate analyses, although univariate analyses showed a detrimental
effect of BRCA2mutations inmodulating OS. The latterwas is in line
with our observation that BRCA2 MBC may be more aggressive,
being of higher stage and histologic grade [44]. Overall, however,
these genes, involved in FBC and MBC susceptibility, do not appear
to play a central role in MBC survival.
In order to characterize our series from a genetic point of view,
we collected a blood sample for each participant, so we recruited a
population-based series of MBC patients still alive at the date of
contact, that is a group of survivors. This represents a limitation in
survival analysis, and to reduce a possible selection bias due to the
loss of early deaths, we considered the blood donation as the start
of observation. However, we also performed a sensitivity analysis
with the date of diagnosis as the start of observation adjusted for
delayed entry or left truncation (time from diagnosis to enrolment),
andwe obtained similar results in terms of death risks associated to
selected individual parameters. Because of the different time scales,
the number of events was lower in the 10 year-period after diag-
nosis considered in this sensitivity analysis and the levels of sta-
tistical significance differed.
Another limitation of our study is that the smoking status was
assessed at diagnosis so it cannot be excluded that some patients
quit smoking after diagnosis.
I. Zanna et al. / The Breast 40 (2018) 85e9190However, the strength of our study is to have a homogeneous
and well characterized population-based series of MBC cases with
detailed information about clinico-pathological, genetic and
lifestyle-related variables.
In conclusion, our study allowed us to explore the factors
influencingMBC survival, suggesting an important role for smoking
history and FGFR2 rs2981582 variant. Nevertheless, our findings
should be regarded with caution and their clinical implications are
at present uncertain. On one hand, having identified smoking as an
unfavourable but potentially modifiable prognostic factor, may be
of importance to public health because suggests the possibility to
activate tertiary prevention protocols for promoting smoking
cessation in MBC cases. On the other hand, having identified FGFR2
rs2981582 variant as favourable prognostic factor supports the
hypothesis that survival in MBC may be influenced by a distinct set
of germline variants among those influencing susceptibility.
These results provide interesting clues for further research
aimed at elucidating the possible role of lyfestyle and genetic fac-
tors onMBC survival. Large-scale multicenter studies arewarranted
to verify the importance of these factors in this understudied
disease.
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